Tian An Medicare Limited

SEHK:383 Stock Report

Market Cap: HK$890.5m

Tian An Medicare Past Earnings Performance

Past criteria checks 3/6

Tian An Medicare has been growing earnings at an average annual rate of 5.7%, while the Healthcare industry saw earnings growing at 11.8% annually. Revenues have been growing at an average rate of 6.7% per year. Tian An Medicare's return on equity is 2.4%, and it has net margins of 1.9%.

Key information

5.7%

Earnings growth rate

5.1%

EPS growth rate

Healthcare Industry Growth11.3%
Revenue growth rate6.7%
Return on equity2.4%
Net Margin1.9%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

China Medical & HealthCare Group's (HKG:383) Returns On Capital Not Reflecting Well On The Business

Feb 02
China Medical & HealthCare Group's (HKG:383) Returns On Capital Not Reflecting Well On The Business

Returns On Capital Signal Difficult Times Ahead For China Medical & HealthCare Group (HKG:383)

Oct 26
Returns On Capital Signal Difficult Times Ahead For China Medical & HealthCare Group (HKG:383)

Is China Medical & HealthCare Group (HKG:383) Using Debt In A Risky Way?

Sep 30
Is China Medical & HealthCare Group (HKG:383) Using Debt In A Risky Way?

China Medical & HealthCare Group (HKG:383) Might Have The Makings Of A Multi-Bagger

Dec 10
China Medical & HealthCare Group (HKG:383) Might Have The Makings Of A Multi-Bagger

We Think China Medical & HealthCare Group (HKG:383) Has A Fair Chunk Of Debt

Apr 08
We Think China Medical & HealthCare Group (HKG:383) Has A Fair Chunk Of Debt

Do Institutions Own China Medical & HealthCare Group Limited (HKG:383) Shares?

Feb 14
Do Institutions Own China Medical & HealthCare Group Limited (HKG:383) Shares?

Is China Medical & HealthCare Group (HKG:383) A Risky Investment?

Dec 22
Is China Medical & HealthCare Group (HKG:383) A Risky Investment?

Revenue & Expenses Breakdown

How Tian An Medicare makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SEHK:383 Revenue, expenses and earnings (HKD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 241,629322290
31 Mar 241,599212330
31 Dec 231,569112370
30 Sep 231,516-322460
30 Jun 231,463-782570
31 Mar 231,450-1012580
31 Dec 221,438-1242590
30 Sep 221,464-1152450
30 Jun 221,491-1072310
31 Mar 221,477-1222280
31 Dec 211,463-1372250
30 Sep 211,447-1272320
30 Jun 211,430-1162380
31 Mar 211,312-1142330
31 Dec 201,194-1122280
30 Jun 201,099-812380
31 Mar 201,163-402400
31 Dec 191,22812430
30 Jun 191,196352460
31 Mar 191,168-82450
31 Dec 181,139-522430
30 Sep 181,120-942460
30 Jun 181,101-1372480
31 Mar 181,115-1982490
31 Dec 171,130-2582490
30 Sep 171,207-1652450
30 Jun 171,284-722410
31 Mar 171,791-1432510
31 Dec 162,297-2142610
30 Sep 162,349-4982430
30 Jun 162,400-7832250
31 Mar 161,787-3751950
31 Dec 151,175331650
30 Sep 159451311530
30 Jun 157152281410
31 Mar 158592331970
31 Dec 141,0032372530
30 Sep 141,0505822320
30 Jun 141,0969282110
31 Dec 13219-363-40

Quality Earnings: 383 has high quality earnings.

Growing Profit Margin: 383 became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 383 has become profitable over the past 5 years, growing earnings by 5.7% per year.

Accelerating Growth: 383 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 383 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (-16.9%).


Return on Equity

High ROE: 383's Return on Equity (2.4%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies